Your browser doesn't support javascript.
loading
Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres.
McCaughan, Georgia J; Verma, Anvita; Ling, Silvia; Lavee, Orly; Moore, John J; Bryant, Adam.
Affiliation
  • McCaughan GJ; Department of Haematology, St Vincent's Hospital, Sydney, NSW, Australia. Georgia.mccaughan@svha.org.au.
  • Verma A; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. Georgia.mccaughan@svha.org.au.
  • Ling S; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Lavee O; Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia.
  • Moore JJ; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Bryant A; Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia.
Bone Marrow Transplant ; 56(3): 738-740, 2021 03.
Article in En | MEDLINE | ID: mdl-33077903
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Limits: Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2021 Type: Article Affiliation country: Australia
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Limits: Humans Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2021 Type: Article Affiliation country: Australia